Related references
Note: Only part of the references are listed.O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
F Meric-Bernstam et al.
ANNALS OF ONCOLOGY (2018)
Structure-based design of targeted covalent inhibitors
Richard Lonsdale et al.
CHEMICAL SOCIETY REVIEWS (2018)
Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors
Yuming Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors
Xueqiang Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors
Ken A. Brameld et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
Targeted Covalent Inhibitors for Drug Design
Thomas A. Baillie
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Federica Biello et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2016)
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
The ins and outs of selective kinase inhibitor development
Susanne Mueller et al.
NATURE CHEMICAL BIOLOGY (2015)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Margit Hagel et al.
CANCER DISCOVERY (2015)
X-ray origins: protection or paranoia?
Natalie Johnson et al.
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES (2015)
SHELXT - Integrated space-group and crystal-structure determination
George M. Sheldrick
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES (2015)
DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors
Zhifeng Huang et al.
ACS CHEMICAL BIOLOGY (2015)
Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches
A. Rambaldi et al.
LEUKEMIA (2015)
A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases
Stefan G. Kathman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance
Phillip A. Schwartz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Li Tan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Fibroblast growth factor receptors, developmental corruption and malignant disease
Fergal C. Kelleher et al.
CARCINOGENESIS (2013)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities
Hiroaki Ochiiwa et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Tjeerd Barf et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Anticancer molecules targeting fibroblast growth factor receptors
Guang Liang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma
Hung Huynh et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2011)
Protein identification using MS/MS data
John S. Cottrell
JOURNAL OF PROTEOMICS (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
A neutron-diffraction study of the low-cycle fatigue behaviour of an austenitic stainless steel 316.
Adelaide Dubreuil et al.
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES (2010)
Construction of recombinant FGFR1 containing full-length gene and its potential application
Yali Zhou et al.
PLASMID (2010)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
A short history of SHELX
George M. Sheldrick
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES (2008)
The selectivity of protein kinase inhibitors: a further update
Jenny Bain et al.
BIOCHEMICAL JOURNAL (2007)
Novel inhibitor for fibroblast growth factor receptor tyrosine kinase
Naparat Kammasuda et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Radiation damage in macromolecular cryocrystallography
Raimond B. G. Ravelli et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2006)
Structural bioinformatics-based design of selective, irreversible kinase inhibitors
MS Cohen et al.
SCIENCE (2005)
Tyrosine kinase receptors as attractive targets of cancer therapy
A Bennasroune et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2004)
'Cool' crystals: macromolecular cryocrystallography and radiation damage
E Garman
CURRENT OPINION IN STRUCTURAL BIOLOGY (2003)
Blu-Ice and the Distributed Control System:: software for data acquisition and instrument control at macromolecular crystallography beamlines
TM McPhillips et al.
JOURNAL OF SYNCHROTRON RADIATION (2002)
The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells
MJ Cross et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
LK Shawver et al.
CANCER CELL (2002)
Share Paper
